Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||- / 1||- / OT|
Administered by: Other Purchased by: ??
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? Yes
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Preexisting Conditions: Medical History/Concurrent Conditions: Hypercholesterolaemia; Hypertension
Diagnostic Lab Data:
CDC 'Split Type': JPPFIZER INC2021656916
Write-up: Urticaria; This is a spontaneous report from a contactable physician received via COVID-19 Adverse Event Self-Reporting Solution (COVAES). The patient was a non-pregnant 70-year-old female. It was unknown whether the patient receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received Hypertension, Hypercholesterolaemia prescription drugs within 2 weeks of vaccination. It was unknown whether the patient had been diagnosed with COVID-19. On 31May2021(the day of vaccination), the patient received the first single dose of BNT162B2 (COMIRNATY, Solution for injection, Lot number unknown) intramuscular for COVID-19 immunization. On 03Jun2021(the day after vaccination), the patient experienced Urticaria. The reporter stated the event(s) results in doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered with treatment including Bepotastine Besilate orally. It was unknown whether the patient has been tested for COVID-19 since the vaccination. Information about lot/batch number cannot be obtained.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166